Exocrine Pancreatic Insufficiency (EPI) Market Size, Share and Growth Outlook, 2026

Exocrine Pancreatic Insufficiency (EPI) Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Exocrine Pancreatic Insufficiency (EPI) Market size is forecast to increase from $4.04 Billion in 2026 to $6.69 Billion in 2034 at a CAGR of 6.5% between 2026 and 2034.

The Exocrine Pancreatic Insufficiency (EPI) market report provides detailed analysis and outlook of Exocrine Pancreatic Insufficiency (EPI) segments including By Therapy Type (Pancreatic Enzyme Replacement Therapy, Nutritional Therapy & Supplements), By Disease Etiology (Chronic Panclientitis, Cystic Fibrosis, Pancreatic Cancer, Diabetes Mellitus, Gastrointestinal Surgeries ), By Drug Type (Creon, Zenpep, Pancreaze, Viokace, Other Prescriptions & Generics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Exocrine Pancreatic Insufficiency (EPI) Industry Overview

Strategic Pipeline Refocus Toward Enzyme Replacement and Recombinant Lipase Innovation

The exocrine pancreatic insufficiency (EPI) industry is witnessing a strategic realignment of biopharmaceutical pipelines toward targeted enzyme replacement therapies designed to improve digestive enzyme availability in chronic pancreatic disorders. Leading clinical-stage developers are increasingly concentrating R&D efforts on recombinant, non-animal-derived lipase enzymes such as adrulipase, intended to provide improved therapeutic consistency for patients with chronic pancreatitis and cystic fibrosis-related EPI. This shift reflects a broader industry movement toward biologically engineered pancreatic enzyme replacement therapies (PERT) that aim to enhance stability, reduce variability, and expand treatment access across diverse patient populations. Corporate restructuring and portfolio consolidation efforts are reinforcing this focused approach to gastrointestinal enzyme therapeutics.

Strengthening Clinical Evidence Linking EPI with Systemic Metabolic and Cardiovascular Risk

Emerging clinical evidence is expanding the understanding of EPI beyond digestive dysfunction to include systemic metabolic and cardiovascular implications. Large-scale retrospective cohort analyses using real-world clinical databases indicate that patients with chronic pancreatitis who develop secondary EPI exhibit higher rates of major adverse cardiovascular events and increased all-cause mortality compared to those without EPI. These findings are prompting a shift in clinical research priorities toward integrated metabolic monitoring alongside standard pancreatic enzyme replacement therapy. Additionally, epidemiological studies in diabetic populations highlight a strong association between EPI and cardiovascular disease, reinforcing the need for earlier screening using non-invasive biomarkers such as fecal elastase-1 testing.

Expansion of Clinical Trials and Standardization of Post-Pancreatitis Treatment Protocols

The EPI treatment landscape is evolving through prospective clinical trials evaluating standardized pancreatic enzyme replacement therapies in post-pancreatitis recovery pathways. Multi-center studies are assessing the efficacy of pancrelipase formulations in improving gastrointestinal symptoms such as stool frequency, consistency, and nutrient absorption following acute pancreatitis episodes. These trials aim to establish standardized clinical protocols for long-term management of pancreatic insufficiency, supporting more consistent therapeutic outcomes. The increasing focus on structured patient-reported outcome measures reflects a broader industry trend toward evidence-based optimization of enzyme replacement strategies in both acute and chronic care settings.

Advancements in Early Diagnosis and Pediatric-Focused Enzyme Therapy Development

Pharmaceutical innovation in EPI is increasingly focused on improving early diagnostic capabilities and expanding therapeutic applications in pediatric populations, particularly those affected by cystic fibrosis. The adoption of non-invasive diagnostic tools is enabling earlier identification of pancreatic insufficiency, supporting timely intervention with enzyme replacement therapies. Concurrently, advancements in formulation science are improving drug delivery efficiency and therapeutic bioavailability, enhancing patient adherence and clinical outcomes. The integration of early screening protocols with next-generation enzyme therapies is strengthening the overall treatment continuum and supporting more proactive disease management strategies.

Exocrine Pancreatic Insufficiency (EPI) Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Exocrine Pancreatic Insufficiency (EPI) market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- AbbVie Inc. , Nestlé Health Science , Viatris Inc., Abbott Laboratories , VIVUS, Inc. , Digestive Care, Inc. , Janssen Pharmaceuticals, Inc. , Alcresta Therapeutics, Inc., First Wave BioPharma, Inc. , Nordmark Pharma GmbH. The Exocrine Pancreatic Insufficiency (EPI) market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Exocrine Pancreatic Insufficiency (EPI) industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Exocrine Pancreatic Insufficiency (EPI) Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Exocrine Pancreatic Insufficiency (EPI) companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Exocrine Pancreatic Insufficiency (EPI) markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Exocrine Pancreatic Insufficiency (EPI) Market Competitive Benchmarking and Company Analysis

Leading companies in Exocrine Pancreatic Insufficiency (EPI) industry include- AbbVie Inc. , Nestlé Health Science , Viatris Inc., Abbott Laboratories , VIVUS, Inc. , Digestive Care, Inc. , Janssen Pharmaceuticals, Inc. , Alcresta Therapeutics, Inc., First Wave BioPharma, Inc. , Nordmark Pharma GmbH. The Exocrine Pancreatic Insufficiency (EPI) market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Exocrine Pancreatic Insufficiency (EPI) Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Exocrine Pancreatic Insufficiency (EPI) market remains one of the strongest-performing segments in the country.
The US Exocrine Pancreatic Insufficiency (EPI) Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Exocrine Pancreatic Insufficiency (EPI) market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Exocrine Pancreatic Insufficiency (EPI) industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Exocrine Pancreatic Insufficiency (EPI) markets

Canada's strong Exocrine Pancreatic Insufficiency (EPI) sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Exocrine Pancreatic Insufficiency (EPI) market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Exocrine Pancreatic Insufficiency (EPI) Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Exocrine Pancreatic Insufficiency (EPI) market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Exocrine Pancreatic Insufficiency (EPI) population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Exocrine Pancreatic Insufficiency (EPI) industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Exocrine Pancreatic Insufficiency (EPI) market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Exocrine Pancreatic Insufficiency (EPI) sales through 2034

France Exocrine Pancreatic Insufficiency (EPI) companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Exocrine Pancreatic Insufficiency (EPI) Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Exocrine Pancreatic Insufficiency (EPI) distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Exocrine Pancreatic Insufficiency (EPI) Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Exocrine Pancreatic Insufficiency (EPI) market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Exocrine Pancreatic Insufficiency (EPI) industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Exocrine Pancreatic Insufficiency (EPI) industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Exocrine Pancreatic Insufficiency (EPI) Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Exocrine Pancreatic Insufficiency (EPI) market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Exocrine Pancreatic Insufficiency (EPI) market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Exocrine Pancreatic Insufficiency (EPI) Market Segmentation

By Therapy Type
Pancreatic Enzyme Replacement Therapy
Nutritional Therapy & Supplements
By Disease Etiology
Chronic Panclientitis
Cystic Fibrosis
Pancreatic Cancer
Diabetes Mellitus
Gastrointestinal Surgeries
By Drug Type
Creon
Zenpep
Pancreaze
Viokace
Other Prescriptions & Generics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online

Top Companies in Exocrine Pancreatic Insufficiency (EPI) Industry

AbbVie Inc.
Nestlé Health Science
Viatris Inc.
Abbott Laboratories
VIVUS, Inc.
Digestive Care, Inc.
Janssen Pharmaceuticals, Inc.
Alcresta Therapeutics, Inc.
First Wave BioPharma, Inc.
Nordmark Pharma GmbH

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa